Zentalis reports 15.9-month median overall survival with azenosertib in Cyclin E1-positive ovarian cancer trial
ZNTL•Zentalis reported 15.9-month median overall survival with azenosertib in its interim DENALI Part 1b results; patients with Cyclin E1-positive tumors had longer median overall survival than those with Cyclin E1-negative tumors.
1. Interim trial results
Zentalis Pharmaceuticals presented interim DENALI Part 1b results for investigational ovarian cancer treatment azenosertib at the ESMO Congress 2026. The findings support Cyclin E1 protein expression as a patient-selection biomarker; safety was consistent with prior reports, though treatment-related adverse events prompted dose changes or discontinuation in some patients. Azenosertib remains in development in the registration-intended DENALI Part 2 study and ASPENOVA Phase 3 confirmatory trial.
